EA201100358A1 - Дабигатран для чрескожной хирургической катетеризации сердца - Google Patents

Дабигатран для чрескожной хирургической катетеризации сердца

Info

Publication number
EA201100358A1
EA201100358A1 EA201100358A EA201100358A EA201100358A1 EA 201100358 A1 EA201100358 A1 EA 201100358A1 EA 201100358 A EA201100358 A EA 201100358A EA 201100358 A EA201100358 A EA 201100358A EA 201100358 A1 EA201100358 A1 EA 201100358A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dabigatran
intertegual
heart
surgical catheterization
catheterization
Prior art date
Application number
EA201100358A
Other languages
English (en)
Inventor
Пол А. Рейлли
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201100358A1 publication Critical patent/EA201100358A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Abstract

В заявке описано новое применение этексилата дабигатрана формулы Iнеобязательно в форме его фармацевтически приемлемых солей, а также новые лекарственные составы, которые можно использовать с указанной целью.
EA201100358A 2008-08-19 2009-08-17 Дабигатран для чрескожной хирургической катетеризации сердца EA201100358A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (en) 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation

Publications (1)

Publication Number Publication Date
EA201100358A1 true EA201100358A1 (ru) 2011-10-31

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100358A EA201100358A1 (ru) 2008-08-19 2009-08-17 Дабигатран для чрескожной хирургической катетеризации сердца

Country Status (19)

Country Link
US (1) US20110301201A1 (ru)
EP (1) EP2328580A1 (ru)
JP (1) JP2012500245A (ru)
KR (1) KR20110044230A (ru)
CN (1) CN102123707A (ru)
AR (1) AR073077A1 (ru)
AU (1) AU2009284217A1 (ru)
BR (1) BRPI0917507A2 (ru)
CA (1) CA2734794A1 (ru)
CL (1) CL2011000361A1 (ru)
CO (1) CO6290686A2 (ru)
EA (1) EA201100358A1 (ru)
EC (1) ECSP11010825A (ru)
IL (1) IL210005A0 (ru)
MA (1) MA32563B1 (ru)
MX (1) MX2011001612A (ru)
NZ (1) NZ591108A (ru)
TW (1) TW201022235A (ru)
WO (1) WO2010020602A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201100756A1 (ru) 2008-11-11 2011-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином
WO2011107427A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
US20150225370A1 (en) * 2012-09-28 2015-08-13 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
CN108354933A (zh) 2013-03-15 2018-08-03 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
MX2015011567A (es) 2013-03-15 2016-04-25 Verseon Corp Halogeno-pirazoles como inhibidores de trombina.
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
LT3261639T (lt) 2015-02-27 2022-11-25 Verseon International Corporation Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
EP3820564A1 (en) 2018-07-13 2021-05-19 Verseon International Corporation Thrombin inhibitors, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485094B2 (de) * 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
CA2587026A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
WO2008009638A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
CL2007002067A1 (es) * 2006-07-17 2008-01-25 Boehringer Ingelheim Int Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras.
CA2666396A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
TW201022235A (en) 2010-06-16
ECSP11010825A (es) 2011-03-31
MX2011001612A (es) 2011-03-04
CO6290686A2 (es) 2011-06-20
IL210005A0 (en) 2011-02-28
US20110301201A1 (en) 2011-12-08
AU2009284217A1 (en) 2010-02-25
CL2011000361A1 (es) 2011-06-17
CA2734794A1 (en) 2010-02-25
MA32563B1 (fr) 2011-08-01
WO2010020602A1 (en) 2010-02-25
AR073077A1 (es) 2010-10-13
EP2328580A1 (en) 2011-06-08
BRPI0917507A2 (pt) 2015-11-17
NZ591108A (en) 2012-11-30
JP2012500245A (ja) 2012-01-05
CN102123707A (zh) 2011-07-13
KR20110044230A (ko) 2011-04-28

Similar Documents

Publication Publication Date Title
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
PH12016500024A1 (en) Bromodomain inhibitor
UY30500A1 (es) Compuestos de azabencimidazolilo
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
UY31189A1 (es) Compuestos heterocíclicos
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
EA201490949A1 (ru) Ингибиторы киназ
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201390934A1 (ru) Композиции и способы модулирования fxr
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA201170832A1 (ru) Пуриновые соединения
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3